HomeQuestion

How do you approach c-KIT mutated, core binding factor (CBF) AML?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Does treating CLL reduce the risk of non-melanoma skin cancers?

Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?

1 Answers

In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide the duration of maintenance POMP therapy?

1 Answers

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

11 Answers

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

11 Answers

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service